Acadia Realty Trust (NYSE:AKR) Q4 2025 Earnings call February 11, 2026 11:00 AM ET Speaker6Welcome to the Acadia Realty Trust Fourth Quarter 2025 Earnings Conference call. At this time, all participants are on a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. Please note that today's conference is being ...

Evolv Technologies Conference Call Summary Company Overview - **Company**: Evolv Technologies - **Industry**: AI-enabled touchless security screening - **Founded**: 2013 - **Key Products**: Evolv Express (for people screening) and Evolv eXpedite (for bag screening) [1][10] Core Insights and Arguments - **Mission**: To make the world a safer and more enjoyable place through innovative security solutions [4] - **Market Need**: The company was inspired by tragic events, including the Boston Marathon bombing and numerous mass shootings, highlighting the urgent need for improved security measures [2][3][4] - **Technology Innovation**: Evolv Technologies focuses on using advanced technology, sensors, and AI to differentiate between weapons and personal items, allowing for quick and efficient screening [7][8][17] - **Operational Efficiency**: The technology aims to reduce wait times and improve the experience for users while maintaining high security standards [10][33] Market Opportunity - **Total Addressable Market (TAM)**: Estimated at $20 billion, targeting sectors such as education, healthcare, sports, entertainment, and industrial workplaces [17] - **Customer Base**: Approximately 1,000 customers, primarily in the U.S., including sports venues, schools, hospitals, and casinos [18][19] - **Growth Potential**: The company sees significant growth opportunities, especially in light of increasing violence and the need for effective security solutions [57][67] Product Features and Performance - **Evolv Express**: Allows individuals to walk through without stopping, identifying concealed threats quickly [10] - **Evolv eXpedite**: Automates bag screening, significantly faster than traditional X-ray systems [13] - **Data Utilization**: The system collects data on screening events, helping customers optimize staffing and security operations [42][44] Challenges and Considerations - **False Positives**: The system experiences nuisance alarms, with rates varying based on settings and environments, but aims to minimize disruption [26][28] - **Market Awareness**: The primary challenge is increasing awareness of the technology and its benefits compared to traditional methods [50][52] - **International Expansion**: Currently, less than 10% of business is international, but there are plans for growth in global markets [66][67] Future Outlook - **Technological Adaptability**: The company is committed to continuously updating its algorithms and technology to address evolving threats [20] - **Long-term Contracts**: Evolv engages customers with four-year non-cancelable contracts, fostering strong relationships and ongoing collaboration [45] - **Network Effect**: The large customer base enhances the effectiveness of the technology through shared learnings and data [46] Additional Insights - **Security Trends**: The company notes a shift in security approaches, with more organizations seeking advanced screening technologies due to recent violent events [29][30] - **Event Security**: Major events like the World Cup and Olympics are driving interest in efficient and effective security solutions [31][33] - **Manufacturing Partnerships**: Evolv has partnered with Plexus for manufacturing, enhancing scalability and operational capacity [37][38] This summary encapsulates the key points discussed during the Evolv Technologies conference call, highlighting the company's mission, market opportunities, product innovations, and future growth strategies.

Summary of Lazard Asset Management Conference Call Company Overview - **Company**: Lazard Asset Management - **AUM**: Approximately $265 billion [1] Key Points and Arguments Leadership Transition - **New CEO**: Chris Hogbin appointed as CEO of Lazard Asset Management in December [1] - **Experience**: Chris brings 30 years of global investment leadership, previously serving as global head of investments at AllianceBernstein [1] Strategic Vision - **Lazard 2030**: The vision set by group CEO Peter Orszag is a key attraction for Chris Hogbin [3] - **Strengths**: Lazard has strong investment and distribution capabilities, but there are areas for improvement [3][4] Priorities for Growth 1. **Delivering Investment Performance**: - Two-thirds of AUM is outperforming its stated benchmark, but there is room for improvement [7] - Appointment of a Chief Investment Officer, Eric Van Nostrand, to oversee portfolio managers and enhance performance [8][9] 2. **Growing the Business**: - Transition year with $8.5 billion of net inflows, excluding a significant client termination [11] - January saw nearly $3 billion in net inflows, indicating positive momentum [11] 3. **Capitalizing on Growth**: - Focus on improving margins without adding costs [12] - Need for operating leverage as the business grows [12] Strategic Business Mix - **Protect and Grow**: Focus on systematic equities, global listed infrastructure, and emerging markets [13] - **Invest and Enhance**: Investment in the investment team and new product development, including a move from 0 to $1 billion in active ETFs [14] - **White Space Opportunities**: - Expansion in public markets, private markets, and wealth management [15][16] M&A Considerations - Organic growth is preferred, but selective M&A may be necessary for expansion [17][20] - Focus on partnerships rather than large acquisitions in private markets [20] Institutional Investor Sentiment - Increasing skepticism among asset owners regarding U.S. market valuations, leading to diversification into international markets [25] - Two-thirds of managed assets are non-dollar denominated, indicating strong international exposure [26] Active ETF Business - Growth from 0 to 7 active ETFs with $1 billion AUM, indicating strong demand for successful strategies [35][36] - Future plans include expanding into Europe and innovating new ETFs [37] Margin Improvement - Current margins are below industry average, with no structural limitations to improvement [42][44] - Focus on growing existing products and rationalizing underperforming strategies [45][46] Distribution and Sales Strategy - Impressive distribution team performance with record gross sales of $55 billion [55] - Need for increased front-line personnel to enhance intermediary relationships [55][57] Wealth Management Opportunities - Wealth business in France is profitable and has growth potential; U.S. wealth business offers unique high-net-worth services [71][72] AI Integration - AI will be leveraged in investment processes, client experience, and operational efficiency [75][76] - Aim to automate routine tasks to allow analysts more time for strategic thinking [76] Closing Remarks - Confidence in Lazard's strengths and long-term growth vectors, contributing to the Lazard 2030 ambitions [78]

Summary of SAB Biotherapeutics Conference Call Company Overview - **Company**: SAB Biotherapeutics (NasdaqCM:SABS) - **Focus**: Development of new medicines for type 1 diabetes, aiming to change the course of the disease rather than just treat symptoms [2][3] Industry Context - **Market Opportunity**: Type 1 diabetes represents a major unmet medical need with no approved drugs currently available, creating a multi-billion dollar market opportunity [3][6] - **Patient Demographics**: Approximately 64,000 new patients are diagnosed with type 1 diabetes each year [6] Key Product Information - **Lead Asset**: SAB-142, an anti-thymocyte immunoglobulin that is fully human [2][15] - **Mechanism of Action**: SAB-142 induces T cell exhaustion while preserving regulatory T cells (Tregs), which is critical for self-tolerance [11][15] - **Clinical Trials**: Currently in a pivotal phase 2b trial named SAFEGUARD, targeting newly diagnosed patients within 100 days of diagnosis [28][43] Clinical Trial Details - **Phase 1 Study**: Completed in 2024, demonstrated safety and absence of serum sickness or anti-drug antibodies [17][22] - **Dosing for SAFEGUARD**: Two doses being tested: 2.5 mg/kg and 1.5 mg/kg [19][20] - **Primary Endpoint**: C-peptide preservation at one year, with a target of 40% preservation considered clinically meaningful [44][47] - **Enrollment Timeline**: Expected to complete enrollment by the end of 2026, with data anticipated in the second half of 2027 [43] Competitive Landscape - **Competitors**: Tzield, which is under review for approval in stage 3 type 1 diabetes, has shown regulatory clarity and a potential path for approval based on C-peptide preservation [53] Commercial Strategy - **Market Preparation**: Early commercial activities are underway, including the hiring of David Zaccardelli as chairman, who has experience in successful drug launches [49] - **Addressable Market**: Focus on newly diagnosed patients and potential expansion to stage 2 patients, which could significantly increase the market size [50][51] Financial Health - **Cash Position**: SAB Biotherapeutics had approximately $140 million in cash at the end of 2025, sufficient to fund operations through 2028 [54] Additional Insights - **Regulatory Strategy**: Engaging with regulatory agencies to ensure a clear path for approval and to establish a favorable safety profile before moving to younger patient populations [29][30] - **Long-term Vision**: The company aims to develop therapies that can preserve beta cell function in earlier stages of type 1 diabetes, potentially leading to a functional cure [50][51]

NNN REIT (NYSE:NNN) Q4 2025 Earnings call February 11, 2026 10:30 AM ET Company ParticipantsJohn Kilichowski - Executive Director of Equity ResearchLinda Tsai - SVPOmotayo Tejumade Okusanya - Managing DirectorRichard Hightower - Managing Director of US REIT ResearchSmedes Rose - DirectorSpenser Glimcher - Managing DirectorStephen A. Horn Jr. - CEOVincent H. Chao - CFOConference Call ParticipantsAlex Fagan - Equity Research AnalystBrad Heffern - Managing Director and Senior Equity Research AnalystJana Galan ...

W. R. Berkley (NYSE:WRB) 2026 Conference February 11, 2026 10:30 AM ET Company ParticipantsRob Berkley - CEO and PresidentConference Call ParticipantsJosh Shanker - Equity Research AnalystJosh ShankerU.S. Financial Services Conference. If you're listening to this podcast, you're in this room, you're in the insurance suite, and we have the session with W. R. Berkley Corporation beginning now. Really pleased to have Rob Berkley, CEO and President of the company, and the time of the Berkley management in gener ...

Summary of Arcturus Therapeutics Conference Call Company Overview - **Company**: Arcturus Therapeutics (NasdaqGM:ARCT) - **Industry**: Biopharmaceuticals, specifically focusing on messenger RNA (mRNA) therapeutics - **Key Products**: Rare disease therapeutics in advanced pipeline, including inhaled mRNA and injectable mRNA for Urea Cycle Disorder (UCD) [1][2] Core Insights and Arguments Inhaled mRNA Therapeutics - Arcturus is a leader in inhaled mRNA, aiming to be the first successful company in this space, which has seen historical failures due to toxicity and intolerability [1] - Current focus is on ARCT-032 for Cystic Fibrosis (CF), with a significant milestone of advancing dosing from 5 mg to 15 mg daily, showing promising results in reducing mucus plugs [3][4] - A Phase 2b study is planned to start in the first half of the year, with a larger cohort of 20 subjects and an extended duration of 12 weeks, aiming for more statistically sound results [8][9] Phase 2b Study Design - The study will incorporate multiple baseline measurements and historical data to strengthen the baseline for lung function parameters [8][9] - Key endpoints include FEV (Forced Expiratory Volume) and LCI (Lung Clearance Index), with the latter being more sensitive to changes in lung function [10][21] - The FDA has indicated that any measurable improvement would be considered significant, especially for the 15%-18% of CF patients who do not respond to existing modulators [13][14] Regulatory Path and Market Opportunity - The regulatory path for ARCT-810, targeting Ornithine Transcarbamylase Deficiency (OTC), is currently uncertain, but upcoming Type C meetings with the FDA are expected to clarify this [31][32] - OTC deficiency represents a significant unmet medical need, particularly in pediatric patients, with no current approved therapies [32][40] - The company believes that normalizing glutamine levels, rather than just ammonia, could be a key biomarker for regulatory approval [38][39] Financial Position - As of September 30, the company reported a strong cash position of $237 million, providing a runway into 2028 without needing to raise funds in the past five years [42][43] - The company has reduced its workforce significantly, indicating a lean operational model focused on CF and OTC programs [43] Additional Important Points - The company is optimistic about the recruitment rate for the Phase 2b study, with over 10 sites in the U.S. and Europe [24][26] - Arcturus is positioned as a leader in the mRNA therapeutic space, with a focus on effective delivery technology that has overcome historical challenges in safety and tolerability [29][30] - The company emphasizes the importance of transient therapies for transient organs like the lung and liver, aligning with their therapeutic approach [28][29] This summary encapsulates the key points discussed during the conference call, highlighting Arcturus Therapeutics' strategic focus, regulatory challenges, and financial health.

NNN REIT (NYSE:NNN) Q4 2025 Earnings call February 11, 2026 10:30 AM ET Company ParticipantsJohn Kilichowski - Executive Director of Equity ResearchLinda Tsai - SVPOmotayo Tejumade Okusanya - Managing DirectorRichard Hightower - Managing Director of US REIT ResearchSmedes Rose - DirectorSpenser Glimcher - Managing DirectorStephen A. Horn Jr. - CEOVincent H. Chao - CFOConference Call ParticipantsAlex Fagan - Equity Research AnalystBrad Heffern - Managing Director and Senior Equity Research AnalystJana Galan ...

Financial Data and Key Metrics Changes - NNN REIT reported a 2.7% growth in AFFO per share for 2025, with core FFO and AFFO both at $0.87 per share, up 6.1% year-over-year [9][10] - The total available liquidity at year-end was $1.2 billion, with a weighted average debt maturity of 10.8 years [3][13] - Annualized base rent increased to $928 million, reflecting an 8% year-over-year growth [11] Business Line Data and Key Metrics Changes - The portfolio consists of 3,692 freestanding single-tenant properties, with occupancy rising to 98.3%, an increase of 80 basis points from the previous quarter [5][11] - 55 out of 64 lease renewals were completed ahead of the average renewal rate of 85%, with rental rates at 104% above prior levels [6] Market Data and Key Metrics Changes - The company completed over $900 million in acquisitions, marking the highest annual volume in its history [2] - The fourth quarter initial cap rate was stable compared to the third quarter, with expectations of slight compression as the year progresses [4][14] Company Strategy and Development Direction - The company maintains a disciplined bottom-up investment approach, focusing on annual dividend growth while managing a top-tier payout ratio [3] - NNN's strategy includes a self-funding business model that can deliver consistent growth in various economic conditions [4] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating a more uncertain macroeconomic environment in 2026, supported by solid financial footing and proactive portfolio management [2][3] - The company anticipates a 3.2% year-over-year growth in AFFO per share for 2026, with a guidance range of $3.52-$3.58 [14] Other Important Information - The company sold 18 income-producing and 42 vacant properties in the fourth quarter, generating $82 million in proceeds [8] - G&A expenses as a percentage of total revenue were 4.9% for the quarter, with a slight increase attributed to promotions and new hires [10][61] Q&A Session Summary Question: Can you provide an update on proactive portfolio management and occupancy levels? - Management indicated that proactive portfolio management involves monitoring tenant renewals and addressing potential issues early, with an ideal occupancy slightly above 98% [18][19] Question: Why is the bad debt assumption set at 75 basis points? - The company explained that 75 basis points is a prudent starting point, reflecting no significant changes in the watchlist and historical performance [21][23] Question: What segments of existing clients are looking to grow more aggressively? - Management noted that auto services and convenience stores are currently the biggest opportunities in the pipeline [32] Question: What is the expected trend for lease termination fees in 2026? - The company anticipates a return to more normalized levels of lease termination fees, estimating around $3 million to $4 million for the year [37] Question: How does the company view competition in the acquisition market? - Management stated that while competition exists, it has not seen significant changes, and it relies on strong relationships to secure deals [39][70] Question: What is the expected trend for occupancy throughout the year? - Management expects occupancy to trend slightly higher, with ongoing sales of vacant assets contributing to this improvement [51] Question: What is the average lease escalator in the portfolio? - The average lease escalator remains at 1.5% for modeling purposes, unaffected by recent acquisition activity [88] Question: How does the company plan to manage refinancing risks? - The company has embedded refinancing assumptions in its guidance, with expectations for a 10-year bond rate around 5.25% [82]

Truist Financial 2026 Conference Summary Company Overview - **Company**: Truist Financial (NYSE:TFC) - **Date**: February 11, 2026 - **Speaker**: Mike Maguire, Chief Financial Officer Key Points Company Evolution and Strategy - The management focus has evolved from a defensive posture post-merger to an offensive strategy aimed at becoming the leading regional bank in its markets [4][5] - Truist aims to accelerate earnings growth and improve profitability, with a positive company-wide attitude and momentum [6] Client Sentiment and Business Growth - Client sentiment is reported to be positive across both wholesale and consumer businesses, with indications of expansion [8] - Businesses have adapted to manage volatility effectively, leading to continued spending and saving among consumers [9][10] Financial Performance and Growth Expectations - Truist expects to achieve a 15% Return on Tangible Common Equity (ROTCE) by 2027, focusing on profitable growth and efficiency [15] - Loan growth is anticipated to be at twice the rate of the previous year, with a focus on maintaining high-quality growth [12][14] Deposit Growth Strategies - Deposit growth is a top priority, with positive momentum observed in the second half of the previous year [19] - Strategies include enhancing retail marketing, focusing on existing clients, and improving treasury management products [20][21] Net Interest Income (NII) and Margin Outlook - NII growth is expected to be driven by an improved funding mix and higher loan growth, with a target net interest margin (NIM) in the low 50s area [25][27] - The company anticipates a gradual increase in NIM, aiming for a level in the three-teens by the end of 2026 [28] Fee Income Growth - Fee income is projected to grow in the mid- to high-single digits, driven by strong performance in markets, treasury, and payments [35][36] - The wealth management segment is expected to grow faster than historical rates due to improved client engagement and service [37][38] Credit Quality and Risk Management - Truist is monitoring potential risks in commercial real estate and consumer discretionary sectors, with a cautious approach to lower-end consumer exposure [59][60] - The company feels well-reserved and does not anticipate significant changes in reserve levels in the near term [62] Regulatory Environment and Capital Management - Truist is well-positioned to adapt to evolving regulatory requirements, with a focus on capital optimization and maintaining a CET1 ratio around 10% by 2027 [33][54] - The company aims to balance organic growth, buybacks, and dividends, targeting a more sustainable payout ratio over time [54] Conclusion and Investor Takeaways - Truist is positioned to drive faster earnings growth with a clear strategic focus and confidence from leadership [66] - The company emphasizes its ability to deliver on profitability and growth targets, making it an attractive investment opportunity [66]